Natick cancer firm appoints chief medical officer
Natick-based Avenge Bio, Inc. has announced the appointment of Dr. Claudio Dansky Ullmann as the company’s chief medical officer.
The biotechnology firm is developing the LOCOcyte immunotherapy platform to treat solid tumors.
"Dr. Dansky Ullmann's extensive expertise in oncology drug development will be instrumental in advancing our lead therapeutic candidate, AVB-001, into the clinic for the treatment of metastatic peritoneal cancers,” said Avenge CEO Michael Heffernan, in a press release.
Ullmann has more than 25 years of experience in clinical oncology and immuno-oncology drug development, according to the release, having most recently served as the chief medical officer of Maryland-based MaxCyte CARMA Cell Therapies. He previously served as senior vice president, head of clinical development at Cambridge’s Infinity Pharmaceuticals and before that was senior medical director, global clinical lead, of oncology clinical research at Takeda Pharmaceutical Co. in Japan.
Ullmann received his medical degree from the Universidad de Buenos Aires in Argentina.
Avenge was founded in 2019 and closed a $45-million Series A financing round in January.
WBJ Web Partners
Most Recent
Most Recent
0 Comments